Application of a Saliva-Based Liquid Biopsy for the Detection of HPV in Patients With Oral Cavity Squamous Cell Carcinoma (OCSCC)
Bulfoni et al.
The finding, in our words
Salivary HPV DNA testing achieved 91.7% sensitivity and 100% specificity against oropharyngeal swab in patients with oral cavity cancer, demonstrating potential for non-invasive self-collection screening programmes and long-term monitoring of HPV-driven disease.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
First-void urine is established as a reliable self-collected specimen for human papillomavirus screening, triage, and post-vaccination surveillance. The use of specialised collection devices and advanced molecular assays supports the integration of non-invasive sampling into routine cervical cancer prevention strategies.
Saliva samples collected using the OMNIgene ORAL device and oral wash samples remain stable for microbiome diversity and relative abundance analyses for up to five years when stored at -80°C. This supports the use of these self-collection methods for long-term prospective biobanking and decentralised clinical studies.
This study found strong agreement between self-collected urine samples tested with the INDICAID HPV assay and clinician-collected swabs tested with the BD Onclarity assay for detecting high-risk HPV. The results suggest that urine-based self-collection offers a reliable alternative for cervical cancer screening, potentially improving access for women who face barriers to standard care.
Single unstimulated whole saliva measurements show high physiological variability, but averaging repeated self-collected samples, particularly in the evening, improves diagnostic reliability. This validation supports the implementation of home-based saliva testing for salivary gland dysfunction.
This study validated a low-cost 3D-printed smartphone attachment and paper sensor for measuring glucose, uric acid and cholesterol in saliva, demonstrating high correlation with standard ELISA results in a small clinical cohort. The authors suggest this platform offers a scalable solution for decentralised diabetes management by balancing sensitivity with affordability.